Showing results (251-260 of 305) with videos related to

Sort By:
Pageof 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2012
Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancerJunyao Xu, Jennifer J Knox, Emin Ibrahimov, et al.
Surgical Oncology|August 28, 2016
Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgeryA E Slagter, D Ryder, B Chakrabarty, et al.
Oncotarget|March 31, 2018
PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumoursAngela Lamarca, Daisuke Nonaka, Wolfgang Breitwieser, et al.
Current Oncology (Toronto, Ont.)|July 25, 2022
The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain MetastasesZainul-Abedin Kapacee, Jennifer Allison, Mohammed Dawod, et al.
European Journal of Immunology|November 1, 2015
Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetesJames E Tooley, Nalini Vudattu, Jinmyung Choi, et al.
Medical Oncology (Northwood, London, England)|September 8, 2019
Outcomes in patients ≥ 80 years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancyA R Lewis, C Cipriano, X Wang, et al.
The Oncologist|November 19, 2020
A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)Mairéad G McNamara, John Bridgewater, Daniel H Palmer, et al.
Cancer Treatment Reviews|March 17, 2021
Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysisEsmeralda Garcia-Torralba, Francesca Spada, Kok Haw Jonathan Lim, et al.
Journal of the National Cancer Institute|January 29, 2017
Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine CarcinomasAngela Lamarca, Thomas Walter, Marianne Pavel, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2015
Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancerMie Grunnet, Ib J Christensen, Ulrik Lassen, et al.
Pageof 31